Lesch K P, Fahlbusch R
Neurochirurgia (Stuttg). 1986 Jul;29(4):99-104. doi: 10.1055/s-2008-1054147.
65% of all intracranial meningiomas and 80% of the intraspinal ones are seen in women. Meningiomas often grow larger and present an increased incidence of clinical signs and symptoms during pregnancy and also in the luteal phase of the menstrual cycle. In this study the oestradiol and progesterone receptors were determined in 30 patients for the first time via the double ligand assay. In about 10% of the patients we found slight oestradiol receptor activity, whereas approx. 63% of the meningiomas examined had specific progesterone receptors. So far there has been no evidence of a definite dependence of receptor concentrations on the sex and age of the patients or on the pathohistology and site of the tumours. Results can be compared with the previously published data on oestradiol and progesterone receptors in meningiomas to a limited extent only, since different biochemical techniques have been employed and also since pre-operative glucocorticoid treatment has been different from study to study. However, we can safely assume that a specific progesterone receptor does exist. Since proliferation of meningiomas with high concentrations of circulating gestagens has been established, the occurrence of significant concentrations of progesterone receptors could imply therapeutic consequences (eg anti-gestagens) in a large proportion of tumours. We may neglect the clinical relevance of the oestradiol receptor because it occurs in low concentrations only. The epidemiological and clinical data on patients with meningiomas, as well as the existence of sex hormone receptors, may contribute to the development of a theory on the pathogenesis of this tumour.
所有颅内脑膜瘤的65%以及脊髓内脑膜瘤的80%见于女性。脑膜瘤通常生长得更大,在孕期以及月经周期的黄体期临床体征和症状的发生率也会增加。在本研究中,首次通过双配体检测法对30例患者的雌二醇和孕酮受体进行了测定。在约10%的患者中,我们发现有轻微的雌二醇受体活性,而在接受检查的脑膜瘤中,约63%有特异性孕酮受体。到目前为止,尚无证据表明受体浓度与患者的性别、年龄或肿瘤的病理组织学及部位有明确关联。由于采用了不同的生化技术,且不同研究之间术前糖皮质激素治疗也有所不同,因此所得结果只能在有限程度上与先前发表的关于脑膜瘤中雌二醇和孕酮受体的数据进行比较。然而,我们可以有把握地认为确实存在特异性孕酮受体。既然已经证实高浓度循环孕激素会促使脑膜瘤增殖,那么大量肿瘤中存在高浓度孕酮受体可能意味着具有治疗意义(如抗孕激素)。我们可以忽略雌二醇受体的临床相关性,因为其浓度很低。有关脑膜瘤患者的流行病学和临床数据以及性激素受体的存在,可能有助于形成关于该肿瘤发病机制的理论。